FERM domain containing 4BGenealiases: 6030440G05Rik · GRSP1
Q-omics provides the consensus-scored FRMD4B profile across patient tissues and cancer cell-line models. FRMD4B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FRMD4B is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, FRMD4B RNA expression shows 20,030 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where FRMD4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMD4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMD4B survival associations across molecular data types. FRMD4B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMD4B RNA expression–survival associations across cancer types. High FRMD4B expression shows unfavorable associations in UVM, LGG and BLCA, but favorable associations in KIRC, SCLC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FRMD4B RNA expression.
This table summarizes FRMD4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FRMD4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMD4B shows lower tumor expression in KICH, LUAD, COAD, THCA and LUSC and higher tumor expression in KIRC. The KICH box plot shows higher FRMD4B RNA expression in normal versus tumor tissue (log2 FC = −2.580, t-test p < 0.001).
This table shows molecular features associated with FRMD4B in patient tissues and cancer cell lines. In patient samples, FRMD4B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMD4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
